Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : VXB-241
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : TCGX
Deal Size : $100.0 million
Deal Type : Series B Financing
Vicebio Secures $100M For RSV/hMPV Vaccine Phase 1 Clinical Study
Details : The financing aims to support the clinical development of VXB-241, which is being evaluated in the early-stage clinical studies for the targeting both RSV and hMPV viruses.
Product Name : VXB-241
Product Type : Vaccine
Upfront Cash : Undisclosed
September 23, 2024
Lead Product(s) : VXB-241
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : TCGX
Deal Size : $100.0 million
Deal Type : Series B Financing
Lead Product(s) : VXB-211
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Medicxi
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : RSV vaccine candidate (VXB-211), best-in-class efficacy as a ready-to-use fully liquid formulation,for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years of age or older.
Product Name : VXB-211
Product Type : Vaccine
Upfront Cash : Inapplicable
July 21, 2022
Lead Product(s) : VXB-211
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Medicxi
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
